Ott Susan M
Department of Medicine, University of Washington, Seattle, WA 98195-6426, USA.
Clin J Am Soc Nephrol. 2008 Nov;3 Suppl 3(Suppl 3):S151-6. doi: 10.2215/CJN.04301206.
A recent Kidney Disease: Improving Global Outcomes report suggested that bone biopsies in patients with chronic kidney disease should be characterized by determining bone turnover, mineralization, and volume. This article focuses on the calculations and interpretation of these measurements. In most cases of renal osteodystrophy, the bone formation rate is roughly similar to the bone resorption rate; therefore, the bone formation indices can be used to describe turnover. It is important to remember that these conventions will not apply in some situations. Activation frequency should not be confused with bone formation rate or bone metabolic unit birth rate. Abnormal mineralization can be described using the osteoid volume, increased osteoid maturation time, or increased mineralization lag time. The concept of bone volume is the easiest to understand, but there is a large error from one biopsy to the next in the same person. There are some difficulties with each of the measurements, and further research in patients with chronic kidney must be done to enable a consensus to be reached about cut points to define categories within the spectrum of renal osteodystrophy and how to evaluate treatment responses.
近期发布的一份《改善全球肾脏病预后》报告建议,慢性肾脏病患者的骨活检应通过测定骨转换、矿化和骨量来进行特征描述。本文重点关注这些测量指标的计算与解读。在大多数肾性骨营养不良病例中,骨形成速率与骨吸收速率大致相似;因此,骨形成指标可用于描述骨转换。需要牢记的是,这些惯例在某些情况下并不适用。激活频率不应与骨形成速率或骨代谢单位生成速率相混淆。异常矿化可用类骨质体积增加、类骨质成熟时间延长或矿化延迟时间延长来描述。骨量的概念最容易理解,但同一人每次活检之间的误差较大。每项测量都存在一些困难,必须对慢性肾脏病患者开展进一步研究,以便就肾性骨营养不良范围内定义分类的切点以及如何评估治疗反应达成共识。